Koye Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 24.05 Cr
as on 08-11-2024
- Paid Up Capital ₹ 4.10 Cr
as on 08-11-2024
- Company Age 2 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 49.95 Cr
as on 08-11-2024
- Satisfied Charges ₹ 30.00 Cr
as on 08-11-2024
About Koye Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 24.05 Cr and a paid-up capital of Rs 4.10 Cr.
The company currently has active open charges totaling ₹49.95 Cr. The company has closed loans amounting to ₹30.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Ravindra Shenoy and Preetish Toraskar serve as directors at the Company.
- CIN/LLPIN
U24290MH2022PTC379913
- Company No.
379913
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Apr 2022
- Date of AGM
30 Nov 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Koye Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Preetish Toraskar  | Director | 04-Apr-2022 | Current |
| Ravindra Shenoy | Director | 04-Apr-2022 | Current |
Financial Performance of Koye Lifesciences.
Koye Lifesciences Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Koye Lifesciences?
In 2023, Koye Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Koye Pharmaceuticals Private LimitedActive 11 years 7 monthsRavindra Shenoy and Preetish Toraskar are mutual person
- Koye Enterprises LlpActive 11 years 5 months
Ravindra Shenoy and Preetish Toraskar are mutual person
- Blue Oyster Enterprises LlpActive 9 years 4 months
Ravindra Shenoy and Preetish Toraskar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Mar 2024 | ₹2.45 Cr | Open |
Others Creation Date: 06 Mar 2024 | ₹47.50 Cr | Open |
Others Creation Date: 07 Feb 2023 | ₹30.00 Cr | Satisfied |
How Many Employees Work at Koye Lifesciences?
Unlock and access historical data on people associated with Koye Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Koye Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Koye Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
